+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Single methotrexate chemotherapy for low-risk gestational trophoblastic tumor



Single methotrexate chemotherapy for low-risk gestational trophoblastic tumor



Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 25(4): 414-417



To investigate the efficacy and toxicity of methotrexate (MTX) give intravenously in the primary treatment of gestational trophoblastic tumor (GTT). A total of 37 patients with low-risk GTT was primarily treated by single MTX in Women's Hospital, School of Medicine, Zhejiang University. Data on the patients' age, clinical stage, WHO classification criteria, antecedent pregnancy, presenting level of human chorionic gonadotropin, courses of chemotherapy required to achieve complete remission, and toxicity related to chemotherapy treatments were collected. Thirty-seven patients with low-risk GTT totally received 137 cycles of MTX between Oct. 1999 and Sep. 2002, 34 patients (91.9%) achieved complete remission. Twenty-nine patients received multiple courses of MTX, complete remission was induced in 26 patients (89.7%). The complete response rates of I stage and III stage were 100.0% and 70.0% (P = 0.03) respectively in patients who were received multiple courses of MTX. However, eight patients received single course of chemotherapy, 7 patients achieved complete remission, and 1 achieved complete remission after another additional course of MTX was conducted. Grade III side effects (WHO criteria) only appeared in 7 courses (5.1%) during MTX treatment. Follow-up data showed that only one patient with single course of chemotherapy relapsed after 6 months. Single MTX chemotherapy may be effective and well tolerated for low-risk GTT.

(PDF emailed within 1 workday: $29.90)

Accession: 050317490

Download citation: RISBibTeXText

PMID: 12974085


Related references

Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof. Zhonghua Yi Xue Za Zhi 85(30): 2109-2112, 2005

Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia. Zhonghua Yi Xue Za Zhi 97(23): 1769-1772, 2018

Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease. Journal of Gynecologic Oncology 28(2): E8, 2016

Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecologic Oncology 125(3): 572-575, 2012

What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecologic Oncology 102(1): 103-110, 2006

Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecologic Oncology 148(1): 161-167, 2017

Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecologic Oncology 96(3): 616-620, 2005

Relapse Rate of Patients with Low-Risk Gestational Trophoblastic Tumor Initially Treated With Single-Agent Chemotherapy. Obstetrical & Gynecological Survey 60(7): 440-441, 2005

Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. American Journal of Obstetrics & Gynecology 172(2 PART 1): 574-579, 1995

Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Gynecologic Oncology 52(1): 114-115, 1994

Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 18(4): 854-859, 2000

Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor. Tumori 73(3): 309-313, 1987

Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecologic Oncology 78(1): 28-31, 2000

Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy. Obstetrics and Gynecology 65(6): 830-836, 1985

Low-risk gestational trophoblastic neoplasia: evaluating the need for initial inpatient treatment during low-dose methotrexate chemotherapy. Journal of Reproductive Medicine 53(7): 525-527, 2008